Overwhelming efficacy - the stats required, page-210

Please excuse the duplication (I did ask this before). Maybe it is a naive question maybe it got lost in the avalanche of great posts on this thread.

Re the Covid 30% readout, I like many have focused on the statistics around the mortality rates (primary end point).

However, does anyone know if there is any precedence by the FDA for weighting of secondary endpoints?

For example we are hearing of many on-going health issues with the current survivors (i.e. heart , lung scarring).

Rel- has regenerative properties would these have any influence on the FDA approval (at the 30% readout) ie if we were just shy of the requires 'p' value?

On a lighter note, I was reading James Cook's biography last night and saw the latin phrase:

"nodum cognita"
(not yet know, but in due course to be revealed)

So relevant to MSB I had to share it.